Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reiterated their buy rating on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a research note released on Thursday, Benzinga reports. They currently have a $17.00 price target on the biotechnology company’s stock. Separately, Wedbush boosted their target price on Alpine Immune Sciences from $17.00 to $19.00 and gave the stock […]
Alpine Immune Sciences (NASDAQ: ALPN) has recently received a number of price target changes and ratings updates: 9/1/2023 – Alpine Immune Sciences had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $19.00 price target on the stock. 8/31/2023 – Alpine Immune Sciences had its “buy” rating reaffirmed by analysts at HC […]
Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Friday, Benzinga reports. They presently have a $19.00 target price on the biotechnology company’s stock. Wedbush’s price objective would suggest a potential upside of 47.29% from the stock’s […]
Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of...
Investment Analysts’ price target changes for Tuesday, August 15th: Arcellx (NASDAQ:ACLX) had its price target increased by HC Wainwright from $49.00 to $50.00. The firm currently has a buy rating on the stock. Arcellx (NASDAQ:ACLX) had its target price increased by Robert W. Baird from $40.00 to $52.00. They currently have an outperform rating on […]